Clinical Trials Directory

Trials / Conditions / Amyloidosis, Hereditary

Amyloidosis, Hereditary

11 registered clinical trials studyying Amyloidosis, Hereditary — 4 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingSoutheastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry
NCT05974644
Virginia Commonwealth University—
RecruitingA Phase 3 Study of NTLA-2001 in ATTRv-PN
NCT06672237
Intellia TherapeuticsPhase 3
RecruitingATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and P
NCT07314268
University of Sao Paulo General Hospital—
Active Not RecruitingMyocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran
NCT05873868
Rennes University Hospital—
Active Not RecruitingProspective Evaluation of NfL as a Biomarker in ATTRv
NCT05879874
Fondazione Policlinico Universitario Agostino Gemelli IRCCS—
RecruitingSubclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
NCT05489549
University of Texas Southwestern Medical Center—
CompletedHELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amy
NCT03759379
Alnylam PharmaceuticalsPhase 3
CompletedENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Fa
NCT02319005
Alnylam PharmaceuticalsPhase 3
CompletedAPOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-
NCT01960348
Alnylam PharmaceuticalsPhase 3
Approved For MarketingExpanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
NCT02939820
Alnylam Pharmaceuticals—
Approved For MarketingATTR Expanded Access Program (EAP) by Ionis
NCT03400098
Ionis Pharmaceuticals, Inc.—